Biomonitoring legislation
This article was originally published in The Rose Sheet
Executive Summary
Language that would have assessed fees on manufacturers of certain personal care products containing "toxic" chemicals to support a statewide biomonitoring initiative was removed from the "Healthy Californians Biomonitoring Program" (SB 1168) June 17. Complicated fee system likely would have faced strong opposition during a California State Assembly Committee on Health hearing June 22, staffers note. Program did not meet state's "Sinclair" model for assessing fees to support public health initiatives, which mandates there must be a direct link between a program's purpose and its means of funding, staffers add. Industry also opposed the listing of chemicals deemed toxic, including triclosan, isopropyl alcohol and certain phthalates...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.